Patents by Inventor Arpita I. Mehta

Arpita I. Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinatorial therapy for protein signaling diseases
    Patent number: 8835360
    Abstract: A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: September 16, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of HHS
    Inventors: Arpita I. Mehta, Lance A. Liotta, Emanuel F. Petricoin
  • Combinatorial therapy for protein signaling diseases
    Patent number: 8168568
    Abstract: A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: May 1, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Arpita I. Mehta, Lance A. Liotta, Emanuel F. Petricoin